Guangxi Liuzhou Pharm Co Ltd (SHG:603368) — Market Cap & Net Worth
Market Cap & Net Worth: Guangxi Liuzhou Pharm Co Ltd (603368)
Guangxi Liuzhou Pharm Co Ltd (SHG:603368) has a market capitalization of $916.62 Million (CN¥6.26 Billion) as of August 1, 2026. Listed on the SHG stock exchange, this China-based company holds position #9121 globally and #2216 in its home market, demonstrating a 2.54% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Guangxi Liuzhou Pharm Co Ltd's stock price CN¥15.77 by its total outstanding shares 397211355 (397.21 Million). See 603368 capital reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
Guangxi Liuzhou Pharm Co Ltd Market Cap History: 2015 to 2026
Guangxi Liuzhou Pharm Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.77 Billion to $916.62 Million (-3.85% CAGR).
Guangxi Liuzhou Pharm Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Guangxi Liuzhou Pharm Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.05x
Guangxi Liuzhou Pharm Co Ltd's market cap is 0.05 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.21x
Guangxi Liuzhou Pharm Co Ltd's market cap is 1.21 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.77 Billion | $6.51 Billion | $208.38 Million | 0.27x | 8.51x |
| 2016 | $1.57 Billion | $7.56 Billion | $321.01 Million | 0.21x | 4.88x |
| 2017 | $1.23 Billion | $9.45 Billion | $401.38 Million | 0.13x | 3.05x |
| 2018 | $955.80 Million | $11.71 Billion | $528.19 Million | 0.08x | 1.81x |
| 2019 | $1.25 Billion | $14.86 Billion | $685.43 Million | 0.08x | 1.82x |
| 2020 | $1.15 Billion | $15.67 Billion | $711.71 Million | 0.07x | 1.62x |
| 2021 | $1.05 Billion | $17.13 Billion | $563.82 Million | 0.06x | 1.86x |
| 2022 | $1.06 Billion | $19.05 Billion | $701.52 Million | 0.06x | 1.51x |
| 2023 | $1.10 Billion | $20.81 Billion | $849.59 Million | 0.05x | 1.29x |
| 2024 | $1.04 Billion | $21.18 Billion | $854.87 Million | 0.05x | 1.21x |
Competitor Companies of 603368 by Market Capitalization
Companies near Guangxi Liuzhou Pharm Co Ltd in the global market cap rankings as of August 1, 2026.
Key companies related to Guangxi Liuzhou Pharm Co Ltd by market ranking:
- McKesson Corporation (NYSE:MCK): Ranked #272 globally with a market cap of $94.62 Billion USD.
- Cencora Inc. (NYSE:COR): Ranked #525 globally with a market cap of $50.53 Billion USD.
- Cardinal Health Inc (NYSE:CAH): Ranked #624 globally with a market cap of $43.01 Billion USD.
- Sigma Healthcare Ltd (AU:SIG): Ranked #1092 globally with a market cap of $24.01 Billion USD ( AU$33.94 Billion AUD).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #272 | McKesson Corporation | NYSE:MCK | $94.62 Billion | $856.19 |
| #525 | Cencora Inc. | NYSE:COR | $50.53 Billion | $311.34 |
| #624 | Cardinal Health Inc | NYSE:CAH | $43.01 Billion | $230.03 |
| #1092 | Sigma Healthcare Ltd | AU:SIG | $24.01 Billion | AU$2.94 |
Guangxi Liuzhou Pharm Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Guangxi Liuzhou Pharm Co Ltd's market cap moved from $1.77 Billion to $ 916.62 Million, with a yearly change of -3.85%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥916.62 Million | -11.50% |
| 2025 | CN¥1.04 Billion | -0.22% |
| 2024 | CN¥1.04 Billion | -5.60% |
| 2023 | CN¥1.10 Billion | +3.66% |
| 2022 | CN¥1.06 Billion | +1.09% |
| 2021 | CN¥1.05 Billion | -8.96% |
| 2020 | CN¥1.15 Billion | -7.73% |
| 2019 | CN¥1.25 Billion | +30.72% |
| 2018 | CN¥955.80 Million | -22.01% |
| 2017 | CN¥1.23 Billion | -21.83% |
| 2016 | CN¥1.57 Billion | -11.54% |
| 2015 | CN¥1.77 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of Guangxi Liuzhou Pharm Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $916.62 Million USD |
| MoneyControl | $916.62 Million USD |
| MarketWatch | $916.62 Million USD |
| marketcap.company | $916.62 Million USD |
| Reuters | $916.62 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Guangxi Liuzhou Pharm Co Ltd
Guangxi LiuYao Group Co., Ltd engages in the wholesale and retail of pharmaceutical products in China. It offers various types of medicines, medical devices, consumables, and test reagents through online pharmacies and terminal physical pharmacies. The company was founded in 1981 and is based in Liuzhou, China.